The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210a prothrombin gene mutation

British Journal of Haematology

Volumn 113, Issue 3, 2001, Pages 630-635

  De Stefano, Valerio ^a   Martinelli, Ida ^b   Mannucci, Pier Mannuccio ^b   Paciaroni, Katia ^a   Rossi, Elena ^a   Chiusolo, Patrizia ^a   Casorelli, Ida ^a   Leone, Giuseppe ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Prothrombin gene mutation; Recurrent venous thromboembolism; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; PROTHROMBIN;

ADOLESCENT; ADULT; ANTICOAGULANT THERAPY; ARTICLE; DEEP VEIN THROMBOSIS; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOGENESIS; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; PROTHROMBIN; PULMONARY EMBOLISM; RECURRENCE; RISK; VENOUS THROMBOSIS;

EID: 0034994092     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02827.x     Document Type: Article

References (23)

1. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes
2. Mutation in blood coagulation factor V associated with resistance to activated protein C
3. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene
4. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: Prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels
5. The prothrombin gene G20210A variant: Prevalence in a UK anticoagulant clinic population
6. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management
7. Prevalence of the factor II G20210A mutation in symptomatic patients with inherited thrombophilia
8. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
9. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden
10. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene
11. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C)
12. Non parametric estimation from incomplete observations
13. Prevalence of the 20210A allele of the prothrombin gene in venous thromboembolism patients
14. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene
15. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with a familial thrombophilia
16. 20210 gene variant
17. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism
18. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families
19. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT)
20. A common genetic variation in the 3′untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
21. The long-term clinical course of acute deep venous thrombosis
22. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis
23. Confidence intervals for reporting results of clinical trials